Pharmaceutical Antitrust

A federal judge in Connecticut <strong><a href="http://www.courthousenews.com/wp-content/uploads/2018/03/Aggrenox.pdf">granted</a></strong> class certification and preliminary approval of a $54 million proposed settlement in an antitrust case claiming drug makers blocked generic alternatives to the stroke medication Aggrenox.

BRIDGEPORT, Conn. – A federal judge in Connecticut granted class certification and preliminary approval of a $54 million proposed settlement in an antitrust case claiming drug makers blocked generic alternatives to the stroke medication Aggrenox.

Categories / Business, Health

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.